<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04069143</url>
  </required_header>
  <id_info>
    <org_study_id>IM033-002</org_study_id>
    <nct_id>NCT04069143</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, Kinetics, and Repeatability of the Novel LPA1 PET Ligand 18F-BMS-986327</brief_title>
  <official_title>An Open-Label Study to Evaluate the Safety, Tolerability, Kinetics, and Repeatability of the Novel Lysophosphatidic Acid Receptor 1 (LPA1) Positron Emission Tomography (PET) Ligand 18F-BMS-986327</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to evaluate Safety,Tolerability, Kinetics, and Repeatability of the Novel&#xD;
      Lysophosphatidic Acid Receptor 1 (LPA1) Positron Emission Tomography (PET) Ligand&#xD;
      18F-BMS-986327.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2019</start_date>
  <completion_date type="Anticipated">May 5, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 5, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events (AEs)</measure>
    <time_frame>30 days after participant's participation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of serious adverse events (SAEs)</measure>
    <time_frame>30 days after participant's participation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Radiation dosimetry calculated from PET- computed tomography (CT) images</measure>
    <time_frame>30 days after participant's participation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Test-retest repeatability</measure>
    <time_frame>30 days after participant's participation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Biodistribution and Lung uptake calculated from PET-CT images in participants with IPF</measure>
    <time_frame>30 days after participant's participation</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Enrollment of Normal Healthy Volunteers (NHV)</condition>
  <condition>and Participants With Idiopathic Pulmonary Fibrosis (IPF)</condition>
  <arm_group>
    <arm_group_label>Part 1:18F-BMS-986327 (Safety Study)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: 18F-BMS-986327 (Test/Retest Study)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3: 18F-BMS-986327 (Distribution in Partcipants with IPF)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>18F-BMS-986327</intervention_name>
    <description>Imaging Agent</description>
    <arm_group_label>Part 1:18F-BMS-986327 (Safety Study)</arm_group_label>
    <arm_group_label>Part 2: 18F-BMS-986327 (Test/Retest Study)</arm_group_label>
    <arm_group_label>Part 3: 18F-BMS-986327 (Distribution in Partcipants with IPF)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding BMS clinical trial participation, please visit&#xD;
        www.BMSStudyConnect.com&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Body weight at least 50kg (110lbs), Body Mass Index (BMI) within 19 to 32 kg/m^2,&#xD;
             inclusive&#xD;
&#xD;
          -  Must be in good health as determined by medical history, physical examination, ECG,&#xD;
             serum/urine biochemistry, hematology, and serology tests&#xD;
&#xD;
          -  Negative hepatitis panel and negative human immunodeficiency virus (HIV)antibody&#xD;
             screens&#xD;
&#xD;
          -  Women of childbearing potential (WOCBP) and men who are sexually active with WOCBP&#xD;
             must use acceptable method(s) of contraception. The individual methods of&#xD;
             contraception and duration should be determined in consultation with the investigator.&#xD;
             WOCBP must follow instructions for birth control when the half-life of the&#xD;
             investigational drug is less than 24 hours, contraception should be continued for a&#xD;
             period of 30 days after the last dose of investigational product.&#xD;
&#xD;
          -  Women must have a negative urine pregnancy test within 24 hours prior to the start of&#xD;
             investigational product.&#xD;
&#xD;
          -  Women must not be breastfeeding.&#xD;
&#xD;
          -  Men who are sexually active with WOCBP must use any contraceptive method with a&#xD;
             failure rate of less than 1% per year. Men that are sexually active with WOCBP must&#xD;
             follow instructions for birth control when the half-life of the investigational drug&#xD;
             is less than 24 hours, contraception should be continued for a period of 90 days after&#xD;
             the last dose of investigational product.&#xD;
&#xD;
          -  Women who are not of childbearing potential (i.e., who are postmenopausal or&#xD;
             surgically sterile) and azoospermic men do not require contraception.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any history or presence of clinically significant respiratory, Gastro Intestinal (GI),&#xD;
             renal, hepatic, pancreatic, hematological, neurological (including history of&#xD;
             seizure), cardiovascular, psychiatric (including known addictive disorders),&#xD;
             musculoskeletal, genitourinary, immunological, or dermatological disorders, including&#xD;
             all cancers&#xD;
&#xD;
          -  Any acute or chronic condition that, in the opinion of the investigator in&#xD;
             consultation with the BMS Medical Monitor, could jeopardize the subject's safety,&#xD;
             tolerability, or pharmacokinetics of 18F-BMS-986327.&quot;&#xD;
&#xD;
          -  Any major surgery within 4 weeks of study drug administration - Existence of a cold,&#xD;
             upper respiratory tract infection, or fever within 5 days prior to check-in&#xD;
&#xD;
          -  Presence or history of any abnormality or illness that may affect absorption,&#xD;
             distribution, metabolism or elimination of the study drug&#xD;
&#xD;
          -  Donation of blood or plasma (exclude the screening visit) within 2 months prior to&#xD;
             check in through end of synthesis (EOS), inclusive&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruiting sites have contact information. Please contact the sites directly. If there is no contact information,</last_name>
    <phone>please email:</phone>
    <email>Clinical.Trials@bms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of the email MUST contain NCT # and Site #.</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Yale Positron Emission Tomography Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520-8048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Carson, Site 0001</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>https://www.bmsstudyconnect.com/s/US/English/USenHome</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 22, 2019</study_first_submitted>
  <study_first_submitted_qc>August 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2019</study_first_posted>
  <last_update_submitted>August 7, 2020</last_update_submitted>
  <last_update_submitted_qc>August 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

